Progesterone Receptor Negative Completed Phase 2 Trials for Tivantinib (DB12200)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01575522Tivantinib in Treating Patients With Recurrent or Metastatic Breast CancerTreatment